Nephrol Dial Transplant (2001) 16: 3-6
© 2001 European Renal Association-European Dialysis and Transplant Association
Pathophysiology of cardiovascular damage in the early renal population
Centre Hospitalier FH Manhes, Fleur-Merogis, France
In renal disease, mechanisms available to compensate for the reduced haemoglobin levels associated with anaemia include increased oxygen extraction from peripheral tissues and, primarily, increased blood flow and changes in blood flow distribution. Haemodynamic changes induced by anaemia include decreases in blood viscosity, peripheral vascular resistance and oxygen delivery, and an increase in sympathetic activity. The overall effect of anaemia is a chronic increase in cardiac output and cardiac work. Under normal conditions, the increased cardiac work and blood flow associated with anaemia results in adaptive left ventricular hypertrophy (LVH)/remodelling and adaptive arterial hypertrophy/remodelling. However, under uraemic conditions these changes lead to maladaptive hypertrophy and arteriosclerosis. In end-stage renal disease (ESRD) patients, increases in both left ventricular end-diastolic volume and mass are related to decreases in haemoglobin. Therefore, LVH progresses in parallel with changes in haemoglobin level and is associated with decreased survival in ESRD patients receiving renal replacement therapy. In conclusion, anaemia is a contributory factor to LVH in renal disease and cardiovascular damage starts at an early stage. Therefore, early intervention to treat anaemia in these patients can prevent or delay this damage.
Keywords: anaemia; cardiovascular remodelling; left ventricular hypertrophy; renal disease; uraemia
Correspondence and offprint requests to: Dr Gerard M. London, Centre Hospitalier FH Manhes, Service de Nephrologie, 8, Grande Rue, F-91700 Fleury-Merogis, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Bacchus, N. O'Mara, H. Manley, and S. Fishbane Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists Ann. Pharmacother., November 1, 2009; 43(11): 1857 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hayakawa, N. Hiramatsu, M. Okamura, H. Yamazaki, S. Nakajima, J. Yao, A. W. Paton, J. C. Paton, and M. Kitamura Acquisition of Anergy to Proinflammatory Cytokines in Nonimmune Cells through Endoplasmic Reticulum Stress Response: A Mechanism for Subsidence of Inflammation J. Immunol., January 15, 2009; 182(2): 1182 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Woo, W. Krzyzanski, A.-M. Duliege, R. B. Stead, and W. J. Jusko Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers J. Clin. Pharmacol., January 1, 2008; 48(1): 43 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kota, K. K. Machavaram, D. N. McLennan, G. A. Edwards, C. J. H. Porter, and S. A. Charman Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model Drug Metab. Dispos., December 1, 2007; 35(12): 2211 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, L. Del Vecchio, and P. Pozzoni PURE RED-CELL APLASIA "EPIDEMIC"--MYSTERY COMPLETELY REVEALED? Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S303 - S307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nakopoulou, A. C. Lazaris, I. Boletis, S. Michail, C. Iatrou, G. Papadakis, S. Athanassiadou, and C. Stathakis The expression of matrix metalloproteinase-11 protein in various types of glomerulonephritis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. M. Lam, J. W. Funder, D. J. Nikolic-Paterson, P. J. Fuller, and M. J. Young Mineralocorticoid Receptor Blockade But Not Steroid Withdrawal Reverses Renal Fibrosis in Deoxycorticosterone/Salt Rats Endocrinology, July 1, 2006; 147(7): 3623 - 3629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hayakawa, Y. Meng, N. Hiramatsu, A. Kasai, K. Yamauchi, J. Yao, and M. Kitamura Priming of Glomerular Mesangial Cells by Activated Macrophages Causes Blunted Responses to Proinflammatory Stimuli J. Immunol., February 15, 2006; 176(4): 2529 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Galkina and K. Ley Leukocyte Recruitment and Vascular Injury in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 368 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Gross and H. F. Lodish Cellular Trafficking and Degradation of Erythropoietin and Novel Erythropoiesis Stimulating Protein (NESP) J. Biol. Chem., January 27, 2006; 281(4): 2024 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Brunkhorst, J. Bommer, J. Braun, M. Haag-Weber, C. Gill, J. Wagner, and T. Wagener Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Amin, H. Tighiouart, D. E. Weiner, P. C. Stark, J. L. Griffith, B. MacLeod, D. N. Salem, and M. J. Sarnak Hematocrit and left ventricular mass: the Framingham Heart study J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1276 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ogawa, K. Shikata, K. Honke, S. Sato, M. Matsuda, R. Nagase, A. Tone, S. Okada, H. Usui, J. Wada, et al. Cerebroside Sulfotransferase Deficiency Ameliorates L-selectin-dependent Monocyte Infiltration in the Kidney after Ureteral Obstruction J. Biol. Chem., January 16, 2004; 279(3): 2085 - 2090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Griffith, D. N. Reddan, P. S. Klassen, and W. F. Owen Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2479 - 2482. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Hudson and K. S. Schonder Advances in Anemia Management in Chronic Kidney Disease Journal of Pharmacy Practice, December 1, 2002; 15(6): 437 - 455. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Sarnak, H. Tighiouart, G. Manjunath, B. MacLeod, J. Griffith, D. Salem, and A. S. Levey Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (aric) study J. Am. Coll. Cardiol., July 3, 2002; 40(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|